<DOC>
	<DOCNO>NCT02013141</DOCNO>
	<brief_summary>This multicenter , open-label , single-dose pharmacokinetic ( PK ) study . Infants , child , adolescent receive single 10 mg/kg dose telavancin infuse intravenously ( IV ) 60 minute</brief_summary>
	<brief_title>Telavancin Pediatric PK Study ( Ages &gt; 3 Months 17 Years )</brief_title>
	<detailed_description />
	<mesh_term>Bacterial Infections</mesh_term>
	<mesh_term>Gram-Positive Bacterial Infections</mesh_term>
	<mesh_term>Telavancin</mesh_term>
	<criteria>Subject age &gt; 3 month 17 year ( inclusive ) weight within 3rd 97th percentile ( inclusive ) age sex Subject require recently complete systemic antibiotic therapy treatment prevention know suspected bacterial infection Subject estimate creatinine clearance &lt; 50 mL/min/1.73 m2 ( Schwartz equation ) Subject history allergy hypersensitivity glycopeptide antibiotic ( e.g. , vancomycin ) , telavancin , formulation excipients Subject clinically relevant cardiac abnormality , opinion investigator Subject treat investigational drug within 30 day five halflives , whichever longer , study entry</criteria>
	<gender>All</gender>
	<minimum_age>3 Months</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Gram positive bacteria</keyword>
	<keyword>Telavancin</keyword>
	<keyword>VIBATIV</keyword>
	<keyword>Pediatric</keyword>
	<keyword>Pharmacokinetics</keyword>
</DOC>